The European Society for Blood and Marrow Transplantation (EBMT) has released its ninth special report on indications for hematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy. The report provides updated guidance for clinicians treating hematological diseases, solid tumors, and immune disorders.
The work is published in the journal Bone Marrow Transplantation.
Over the past two decades, EBMT has refined its recommendations to align with evolving clinical and scientific developments. The 2025 report underscores the importance of harmonizing practices across transplant centers to improve patient outcomes and facilitate meaningful data aggregation. It also highlights the growing role of innovative therapies, such as CAR-T and advanced therapy medicinal products (ATMPs), in transforming treatment paradigms.
The manuscript outlines available data, general guidance, and key references, complemented by disease-specific tables that provide concise recommendations for HCT and CAR-T indications based on disease status, donor availability, and level of evidence in both adult and pediatric populations. It also addresses advances in gene therapy, emphasizes the importance of quality standards such as JACIE certification, and encourages comprehensive reporting to the EBMT Registry to strengthen real-world evidence and long-term outcome evaluation.
A multidisciplinary approach is recommended to balance disease risk, procedural risks, and alternative strategies, with a focus on survival and quality of life.
“These recommendations aim to support clinicians in optimizing treatment strategies across EBMT centers, ensuring that patients benefit from the most up-to-date advances in cellular and gene therapies,” said Raffaella Greco, co-lead author.
“Since the last edition, innovative cellular and gene therapies have entered clinical practice across several indications, significantly influencing decision-making. We strongly encourage every EBMT center to download the updated recommendations and integrate them into daily practice to ensure consistency and the highest quality of care for patients.” added Annalisa Ruggeri, co-lead author.
More information:
R. Greco et al, Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations, Bone Marrow Transplantation (2025). DOI: 10.1038/s41409-025-02701-3
Provided by European Society for Blood and Marrow Transplantation
Citation:
Clinical practice recommendations for haematopoietic cell transplantation and CAR-T therapy, new for 2025 (2025, October 2)
retrieved 2 October 2025
from https://medicalxpress.com/news/2025-10-clinical-haematopoietic-cell-transplantation-car.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
